Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (Quetiapine Fumarate)

Neuropsychopharmacology

Volumn 21, Issue 2, 1999, Pages 211-217

  Tascedda, F ^a,b   Lovati, E ^a   Blom, J M C ^b,c   Muzzioli, P ^b   Brunello, N ^a,b   Racagni, G ^a,c   Riva, M A ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

Author keywords

AMPA; Clozapine; Gene expression; Haloperidol; Neuroleptic; NMDA; Schizophrenia

Indexed keywords

AMPA RECEPTOR; CLOZAPINE; GLUTAMATE RECEPTOR; HALOPERIDOL; QUETIAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; HUMAN; IMMUNOBLOTTING; MALE; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY; RIBONUCLEASE PROTECTION ASSAY; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; CORPUS STRIATUM; DIBENZOTHIAZEPINES; GENE EXPRESSION REGULATION; HALOPERIDOL; HIPPOCAMPUS; MALE; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0033051436     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(99)00034-2     Document Type: Article

References (36)

1. Andreasen N.C., Nasrallah H.A., Dunn V., Olson S.C., Grove W.M., Ehrhardt J.C., Coffman J.A., Crossett J.H.W. Structural abnormalities in the frontal system in schizophrenia. Arch Gen Psychiatry. 43:1986;136-144.
2. Arndt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidences. Neuropsychopharmacology. 18:1998;63-101.
3. Benes F.M., Sorensen I., Bird E.D. Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr Bull. 17:1991;597-608.
4. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry. 49:1992;206-215.
5. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry. 49:1992;921-926.
6. Brené S., Messer C., Nestler E.J. Expression of messenger RNAs encoding ionotropic glutamate receptors in rat brain. Regulation by haloperidol Neuroscience. 84:1998;813-823.
7. Cadenhead K.S., Geyer M.A., Braff D.L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorders. Am J Psychiatry. 150:1993;1862-1867.
8. Caine S.B., Geyer M.A., Swerdlow N.R. Hippocampal modulation of acoustic startle and prepulse inhibition in the rat. Pharmacol Biochem Behav. 43:1992;1201-1208.
9. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease. Trend Neurosci. 13:1990;272-276.
10. Chomczynski P., Sacchi N. Single step method of RNA isolation by guanidium thiocyanate-chloroform extraction. Anal Biochem. 162:1987;156-159.
11. Deutch A.Y., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charnay D.S. Mechanisms of action of atypical antipsychotic drugs - Implications for novel therapeutic strategies for schizophrenia. Schizophr Res. 4:1991;121-156.
12. DiChiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum. Ach/dopamine/NMDA interactions Trend Neurosci. 17:1994;228-232.
13. Donnelly E.F., Weinberger D.R., Waldman I.N., Wyatt R.J. Cognitive impairment associated with morphological brain abnormalities in computed tomography in chronic schizophrenic patients. J Nerv Ment Dis. 168:1980;305-308.
14. Eastwood Sl., Burnet P.W.J., Harrison P.J. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia. Molec Brain Res. 44:1997;92-98.
15. Ellenbroek B.A. Treatment of schizophrenia. a clinical and preclinical evaluation of neuroleptic drugs Pharmacol Ther. 57:1993;1-78.
16. Ellenbroek B.A., Lubbers L.J., Cools A.R. Activity of "seroquel" (ICI 204,636) in animal models for atypical properties of antipsychotics. A comparison with clozapine Neuropsychopharmacology. 15:1996;406-416.
17. Fink-Jensen A., Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett. 182:1994;115-118.
18. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci. 15:1995;2453-2461.
19. Goldstein J.M. Preclinical profile of Seroquel (quetiapine). An atypical antipsychotic with clozapine-like pharmacology Holliday S.G., Ancill R.J., MacEwan G.W. Schizophrenia. Breaking Down the Barriers:1996;177-208 John Wiley & Sons Ltd, New York.
20. TM). A dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials CNS Drug Reviews. 1:1995;50-73.
21. Healy D.J., Meador-Woodruff J.H. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Mol Brain Res. 47:1997;331-338.
22. Hollmann M., Heinemann S. Cloned glutamate receptors. Rev Neurosci. 17:1994;31-108.
23. Jeste D.V., Lohr J.B. Hippocampal pathologic findings in schizophrenia. A morphometric study Arch Gen Psychiatry. 46:1989;1019-1024.
24. Kinon B.J., Lieberman J.A. Mechanisms of action of atypical antipsychotic drugs. A critical analysis Psychopharmacology. 124:1996;2-34.
25. Lieberman J.A., Koreen A.R. Neurochemistry and neuro-endocrinology of schizophrenia. A selective review Schizophrenia Bull. 19:1993;371-429.
26. Meltzer H.Y. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 17:1991;263-287.
27. Nielsen E.B., Lyon M. Evidence for cell loss in corpus striatum after long term treatment with a neuroleptic drug (flupentixol) in rats. Psychopharmacology. 59:1978;85-89.
28. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
29. Reijmers L.G.J.E., Vanderheyden P.M.L., Peeters B.W.M.M. Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur J Pharmacol. 272:1995;131-138.
30. Riva M.A., Tascedda F., Lovati E., Racagni G. Regulation of NMDA receptor subunits in the rat brain following acute and chronic exposure to antipsychotic drugs. Mol Brain Res. 50:1997;136-142.
31. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther. 271:1994;1058-1066.
32. Seeburg P.H. The TINS/TiPS lecture; the molecular biology of mammalian glutamate receptor channels. Trend Neurosci. 6:1993;359-365.
33. TM (ICI 204,636). and haloperidol administration on ΔFosB-like immunoreactivity in the rodent forebrain Eur J Neurosci. 8:1996;927-936.
34. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
35. Weinberger D.R., Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia. A search for common ground Schizophrenia Res. 16:1995;87-110.
36. Yoshida Y., Ono T., Kawano K., Miyagishi T. Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res. 639:1994;139-148.